New Insider David I. Sandoval Joins Milestone Pharma, Files Form 3
| Field | Detail |
|---|---|
| Company | Sandoval David I. |
| Form Type | 3 |
| Filed Date | Mar 23, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: insider-filing, form-3, new-insider, ownership-disclosure
TL;DR
**New insider David I. Sandoval just filed a Form 3 for Milestone Pharmaceuticals, signaling his initial stake.**
AI Summary
David I. Sandoval, a new insider at Milestone Pharmaceuticals Inc. (CIK: 0001408443), filed a Form 3 on March 23, 2026, indicating his initial beneficial ownership of the company's securities as of March 17, 2026. This filing is a standard regulatory requirement for new officers, directors, or significant shareholders, signaling his official connection to the company. For investors, this matters because it introduces a new key player whose future trading activity (buys or sells) will be closely watched for insights into the company's health and prospects.
Why It Matters
This filing introduces David I. Sandoval as a new insider at Milestone Pharmaceuticals, meaning his future stock transactions could provide signals about the company's outlook.
Risk Assessment
Risk Level: low — A Form 3 is a routine disclosure for new insiders and doesn't inherently indicate positive or negative news, but rather transparency.
Analyst Insight
Smart investors should add David I. Sandoval to their watchlists for Milestone Pharmaceuticals Inc., as any future Form 4 filings (showing buys or sells) could provide valuable insights into insider sentiment.
Key Players & Entities
- Sandoval David I. (person) — Reporting Person, new insider at Milestone Pharmaceuticals Inc.
- Milestone Pharmaceuticals Inc. (company) — Issuer of the securities
- 0001408443 (company) — CIK for Milestone Pharmaceuticals Inc.
- 0002012430 (person) — CIK for David I. Sandoval
FAQ
What is the purpose of this Form 3 filing by David I. Sandoval?
This Form 3, filed on March 23, 2026, serves as an 'Initial statement of beneficial ownership of securities' for David I. Sandoval, indicating his first reportable ownership of Milestone Pharmaceuticals Inc. securities as of the period of report, March 17, 2026.
Which company is associated with this filing?
The issuer associated with this filing is Milestone Pharmaceuticals Inc., with CIK 0001408443. Their business address is 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 MONTREAL A8 H4M 2X6.
Filing Stats: 467 words · 2 min read · ~2 pages · Grade level 8.8 · Accepted 2026-03-23 18:51:28
Filing Documents
- form3-03232026_100323.html (3)
- form3-03232026_100323.xml (3) — 3KB
- ex24-03232026_100323.htm (EX-24) — 5KB
- 0002012430-26-000002.txt ( ) — 10KB
From the Filing
SEC FORM 3 SEC Form 3 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5 1. Name and Address of Reporting Person * Sandoval David I. (Last) (First) (Middle) C/O MILESTONE PHARMACEUTICALS INC. 1111 DR. FREDERIK-PHILIPS BLVD, STE 420 (Street) MONTREAL H4M 2X6 (City) (State) (Zip) QUEBEC, CANADA (Country) 2. Date of Event Requiring Statement (Month/Day/Year) 03/17/2026 3. Issuer Name and Ticker or Trading Symbol Milestone Pharmaceuticals Inc. [ MIST ] 3a. Foreign Trading Symbol 5. If Amendment, Date of Original Filed (Month/Day/Year) 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) GC & Chief Compliance Officer 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (right to buy) (1) 01/19/2036 Common Shares 400,000 $ 1.96 D Explanation of Responses: 1. One-fourth (1/4th) of the shares subject to the option vest on January 19, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. /s/ David Sandoval 03/27/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 3: SEC 1473 (03-26)